Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAB117-HC in Acute Traumatic Spinal Cord Injury
NCT02917291Phase 2Unknown
- Sponsor
- Ferrer
- Start
- Dec 2016
- Primary completion
- Jul 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FAB117-HC in spinal cord injury (SCI) (3 arms), sponsored by Ferrer. Primary endpoint: Number of adverse events at 1 year. Status: unknown.
02
Drugs
FAB117-HC
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02917291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917291.